



PAN AMERICAN HEALTH ORGANIZATION
WORLD HEALTH ORGANIZATION



29th DIRECTING COUNCIL
35th SESSION OF THE REGIONAL COMMITTEE

Washington D.C., 26 September – 3 October 1983

RESOLUTION

CD29.R30

**TECHNICAL DISCUSSIONS ON "POLICIES FOR THE
PRODUCTION AND MARKETING OF ESSENTIAL DRUGS"**

THE 29th DIRECTING COUNCIL,

Having examined the Report of the Technical Discussions (Document CD29/DT/4) held during the Council Meeting, which had before it Document CD29/DT/1;1

Aware of the importance of ensuring the availability of essential drugs to all sectors of the population and of the need to identify appropriate administrative, technical, and financial mechanisms to achieve this goal;

Recalling Resolutions WHA31.32 and WHA35.272 of the World Health Assembly and Resolution XXVII of the XX Pan American Sanitary Conference, which recommended that Member Countries develop comprehensive national drug policies; and

Noting the restrictions and costs associated with the research, development, and production of drugs and the transfer of appropriate technology to the developing world,

RESOLVES

1. To urge Member Governments that have not done so to date to develop intersectoral drug policies linked to priority health needs.
2. To call upon Member Governments to evaluate present production, marketing, quality control, and supply practices with a view to introducing improvements that will permit a reasonable degree of self-sufficiency, control costs, improve distribution channels, and promote appropriate use of drugs.
3. To request the Director to provide, as budgetary resources permit, technical and financial assistance in establishing, in keeping with the recommendations formulated in the Report of the Technical Discussions, a cooperation program at the regional, subregional, and national levels, with a view to advising the Member Governments in all matters relating to the implementation of drug policies and programs.
4. To urge the Director to explore with bilateral and multilateral organizations, foundations, and other private institutions, including pharmaceutical companies and their associations, the possibility of providing the assistance required for the policies and programs referred to in paragraph 3.
5. To request the Director to present to the XXXI Meeting of the Directing Council a report on the progress of the implementation of the Organization's essential drug program.

Sept.–Oct. 1983 OD 192, 78